Cloudbreak Pharma Gets FDA Clearance for Presbyopia Drug CBT-199 Phase 2 Trial
Apr 30, 2026
FDA clears Cloudbreak Pharma's IND for CBT-199, a novel presbyopia eye drop, allowing Phase 2 trials to proceed. The company also advances CBT-001 (Phase 3 for pterygium) and CBT-004 (Phase 3 for pinguecula).